Wikipedia -WSS

Wikipedia

author：knowledge 2025-09-29 20:50:48 - browse：9824

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Ahead of JPM, here's who's profiting most in health care

WSS

Ahead of JPM, here's who's profiting most in health care

David Liu startup to focus on CRISPR delivery

Fed up with FDA, ALS advocates consider a take

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

House panel takes first step toward fixing drug shortages

Covid’s new normal has set in amid another rise in cases

focus

Wikipedia

hotspot

In Memoriam: Notable people who died in 2023

White House finalizes ITC's import ban of latest Apple Watches

How one medical school became remarkably diverse

Videos point to link between seizures and unexplained toddler deaths

Tori Bowie and the unacceptable rates of Black maternal death

What happened to the House vote on health price transparency?

New air purifier tech could be key to improving indoor air quality

U.K. sequencing study surfaces new findings about tumor DNA

Anesthesiologist group: stop taking Ozempic before surgery

FDA weighs limits of animal data in assessing artificial wombs

leisure time

Why the drug industry's warnings on the IRA's impact fall short

PBMs drew scrutiny in House hearing — and so did pharma

What happened to the House vote on health price transparency?

Covid’s new normal has set in amid another rise in cases

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Free Covid tests will again be offered to all U.S. households

hotspot

focus

explore

entertainment